John M. Maris
Children's Hospital of Philadelphia
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name John M. Maris as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:23 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT02780128 · Next Generation Personalized Neuroblastoma TherapyYael P Mosse · terminated · Neuroblastoma, Cancer
- N/ANCT01169376 · Biomarkers in Young Patients With NeuroblastomaChildren's Oncology Group · completed · Neuroblastoma · principal investigator
- N/ANCT01163383 · 131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access ProtocolJohn Maris · available · Neuroblastoma, Childhood Metastatic Pheochromocytoma
- Ph2NCT00293319 · 131 I-MIBG in Treating Patients With Refractory or Relapsed NeuroblastomaUniversity of California, San Francisco · completed · Neuroblastoma · unknown
- Ph2NCT00253435 · N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk NeuroblastomaNew Approaches to Neuroblastoma Therapy Consortium · completed · Neuroblastoma · principal investigator
- Ph1NCT00084422 · N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk NeuroblastomaNew Approaches to Neuroblastoma Therapy Consortium · completed · Neuroblastoma · principal investigator
- Ph1NCT00083135 · N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell TransplantationNew Approaches to Neuroblastoma Therapy Consortium · completed · Neuroblastoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:23 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Administrative CoreP01CA217959 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2017 to 2026 · $95,053 awarded in 2026Same name and institution; not confirmed by an ID
- Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomesR35CA220500 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2017 to 2026 · $1,066,679 awarded in 2026Same name and institution; not confirmed by an ID
- NextGen - CHOPOT2CA278687 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2022 to 2026 · $911,333 awarded in 2026Same name and institution; not confirmed by an ID
- Personalized neuroblastoma vaccinesU01CA281881 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2023 to 2026 · $809,906 awarded in 2026Same name and institution; not confirmed by an ID
- Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood CancersU54CA232568 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2018 to 2022 · $255,100 awarded in 2022Same name and institution; not confirmed by an ID
- Pediatric Preclinical Testing ConsortiumU01CA199287 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2015 to 2021 · $180,518 awarded in 2021Same name and institution; not confirmed by an ID
- Role of LMO1 in Neuroblastoma Initiation and MaintenanceR01CA180692 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2015 to 2019 · $588,631 awarded in 2019Same name and institution; not confirmed by an ID
- The Genetic Basis of Neuroblastoma TumorigenesisR01CA124709 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2008 to 2017 · $614,290 awarded in 2017Same name and institution; not confirmed by an ID
- Isolation of the Neuroblastoma Predisposition GeneR01CA078545 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 1998 to 2006 · $290,510 awarded in 2006Same name and institution; not confirmed by an ID
- Significance of Genetic Alterations in NeuroblastomaR01CA087847 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2002 to 2006 · $225,053 awarded in 2006Same name and institution; not confirmed by an ID
- CHP677: I-MIBG therapy for refractory neuroblastoma: Phase II studyM01RR000240 · NCRR · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 1998 to 2004 · $140 awarded in 2004Same name and institution; not confirmed by an ID
- SIGNIFICANCE OF ALLELIC DELETIONS IN NEUROBLASTOMAU10CA078966 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 1998 to 1999 · $226,050 awarded in 1999Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- NATURAL KILLER CELL BASED IMMUNOTHERAPYP01CA081403 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI ROBERT Charles SEEGER · fiscal years 2000 to 2014
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:23 UTC. The ranking covers the 200 most relevant of 54 PubMed records, and a shared surname and initials can bring in a namesake. All 54 on PubMed
- Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.N Engl J Med · 20101,421 citationsRCR 32.3
- 569 citationsRCR 15.4
- 302 citationsRCR 11.9
- 261 citationsRCR 55.3
- Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.Lancet Oncol · 2013243 citationsRCR 7.5
- Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.Lancet Oncol · 2017234 citationsRCR 7.6
- Outcome after reduced chemotherapy for intermediate-risk neuroblastoma.N Engl J Med · 2010228 citationsRCR 6.1
- Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.J Clin Oncol · 2010189 citationsRCR 4.3
- Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.J Clin Oncol · 2007188 citationsRCR 4.8
- Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.Clin Cancer Res · 2021185 citationsRCR 10.4